Loading clinical trials...
Loading clinical trials...
A Phase 1/1B Multi-Center, Non Randomized, Open-Label, Multiple Dose First-In-Human Study Of DS-6051b, An Oral ROS1 And NTRK Inhibitor, In Subjects With Metastatic and/or Unresectable Solid Tumors
Conditions
Interventions
DS6051b
Locations
6
United States
HonorHealth Research Institute
Scottsdale, Arizona, United States
Chao Family Comprehensive Cancer Center of
Orange, California, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Dana Farber Cancer Inst.
Boston, Massachusetts, United States
New York University
New York, New York, United States
South Texas Accelerated Research Therapeutics
San Antonio, Texas, United States
Start Date
September 1, 2014
Primary Completion Date
March 1, 2019
Completion Date
March 1, 2019
Last Updated
June 24, 2025
NCT06898450
NCT06658951
NCT05101070
NCT05719558
NCT06716138
NCT06307795
Lead Sponsor
Nuvation Bio Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions